HRP20110012T1 - Farmaceutski pripravak - Google Patents
Farmaceutski pripravak Download PDFInfo
- Publication number
- HRP20110012T1 HRP20110012T1 HR20110012T HRP20110012T HRP20110012T1 HR P20110012 T1 HRP20110012 T1 HR P20110012T1 HR 20110012 T HR20110012 T HR 20110012T HR P20110012 T HRP20110012 T HR P20110012T HR P20110012 T1 HRP20110012 T1 HR P20110012T1
- Authority
- HR
- Croatia
- Prior art keywords
- tablet
- layer according
- serum concentrations
- spray
- sorbitol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims abstract 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract 7
- 239000000600 sorbitol Substances 0.000 claims abstract 7
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims abstract 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract 6
- 229960005187 telmisartan Drugs 0.000 claims abstract 6
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims abstract 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims abstract 2
- 210000002966 serum Anatomy 0.000 claims 8
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 3
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 238000002156 mixing Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 102000004895 Lipoproteins Human genes 0.000 claims 2
- 108090001030 Lipoproteins Proteins 0.000 claims 2
- 201000001068 Prinzmetal angina Diseases 0.000 claims 2
- 208000007718 Stable Angina Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- -1 control of pH Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 108010074051 C-Reactive Protein Proteins 0.000 claims 1
- 102100032752 C-reactive protein Human genes 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000015439 Phospholipases Human genes 0.000 claims 1
- 108010064785 Phospholipases Proteins 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical group 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000011888 foil Substances 0.000 claims 1
- 229920001903 high density polyethylene Polymers 0.000 claims 1
- 239000004700 high-density polyethylene Substances 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Farmaceutska tableta ili sloj tablete koji sadrže antagonist angiotenzin II receptora telmisartan u amorfnom obliku, bazično sredstvo i sorbitol, naznačeni time, da sorbitol ima specifičnu površinu između 0.75-3.5 m2/g, povoljnije je 1.4-3.0 m2/g i najpovoljnije je 2.0-2.5 m2/g. Patent sadrži još 11 patentnih zahtjeva.
Claims (12)
1. Farmaceutska tableta ili sloj tablete koji sadrže antagonist angiotenzin II receptora telmisartan u amorfnom obliku, bazično sredstvo i sorbitol, naznačeni time, da sorbitol ima specifičnu površinu između 0.75–3.5 m2/g, povoljnije je 1.4–3.0 m2/g i najpovoljnije je 2.0–2.5 m2/g.
2. Tableta ili sloj tablete u skladu sa zahtjevom 1, naznačeni time, da sadrže sorbitol koji ima D (0.5) prosječne veličine veličine čestica od 100-350 μm, povoljnije je 120-300 μm i najpovoljnije je od 150-200 μm.
3. Tableta ili sloj tablete u skladu sa zahtjevom 1, naznačeni time, da je bazično sredstvo izabrano između hidroksida alkalijskih metala, bazičnih amino kiselina i meglumina.
4. Tableta ili sloj tablete u skladu sa zahtjevom 1, naznačeni time, da sadrže 10-160 mg, povoljnije je 20-80 mg ili 40-80 mg telmisartana.
5. Tableta ili sloj tablete u skladu sa zahtjevom 1, naznačeni time, da sadrže amorfni telmisartan koji ima prosječnu veličinu čestica < 80 μm, povoljnije je 20-55 μm.
6. Tableta ili sloj tablete u skladu sa zahtjevom 1, naznačeni time, da dodatno sadrže ostala punila ili pomoćna sredstva.
7. Tableta ili sloj tablete u skladu sa zahtjevom 6, naznačeni time, da su ostala punila i pomoćna sredstva izabrana između veziva, podloga, sredstava za raspadanje, lubrikanata, sredstava za kontrolu protoka, sredstava za usporavanje kristalizacije, solubilizatora, boja, sredstava za kontrolu pH, površinski aktivnih sredstava i emulgatora.
8. Tableta ili sloj tablete u skladu sa zahtjevom 1, naznačeni time, da su pripremljeni tako da se raspršivanjem-suši vodena otopina koja sadrži telmisartan i bazično sredstvo tako da se dobije raspršivanjem-osušeni granulat, zatim se miješa navedeni raspršivanjem-osušeni granulat sa sorbitolom da bi se dobila pred-mješavina te se zatim navedena pred-mješavina pomiješa sa lubrikantom da bi se dobila konačna mješavina.
9. Tableta ili sloj tablete u skladu sa zahtjevom 1, naznačeni time, da su pakirani u materijal za pakovanje koji je nepropustan za vlagu poput blister pakiranja od aluminijske folije ili su to polipropilenskih tuba ili HDPE bočica.
10. Postupak izrade tableta ili sloja tableta u skladu sa zahtjevom 1, naznačen time, da se liječi hipertenzija bilo sama ili u kombinaciji s liječenjem ili prevencijom stanja izabranog iz skupine koju čine kronična stabilna angina, vazospastička angina, udar, infarkt miokarda, prolazni ishemijski napadaj, kongestivno srčano zatajenje, kardiovaskularno oboljenje, dijabetes, inzulinska rezistencija, smanjena tolerancija glukoze, pre-dijabetes, dijabetes melitus tipa 2, dijabetička nefropatija, metabolički sindrom (sindrom X), debljina, dislipidemija, hipertriglceridemija, povišene serumske koncentracije C-reaktivnog proteina, povišene serumske koncentracije lipoproteina, povišene serumske koncentracije homocisteina, povišene serumske koncentracije lipoproteina male-gustoće (LDL)-kolesterola, povišene serumske koncentracije lipoprotein-povezane fosfolipaze (A2), smanjene serumske koncentracije lipoproteina velike-gustoće (HDL)-kolesterola, smanjene serumske koncentracije HDL(2b)-kolesterola, smanjene serumske koncentracije adiponektina, spoznajno propadanje i demencija.
11. Postupak u skladu sa zahtjevom 10, naznačen time, da stanje koje se liječi i prevenira je kronična stabilna angina, vazospastička angina, udar, infarkt miokarda, kongestivno srčano zatajenje, dijabetes, dislipidemija ili demencija.
12. Postupak priprave farmaceutske tablete ili sloja tablete u skladu sa zahtjevom 1, naznačen time, da sadrži raspršivanjem-sušenje vodene otopine koja sadrži telmisartan i bazično sredstvo da bi se dobio raspršivanjem-osušen granulat, zatim miješanje navedenog raspršivanjem-osušenog granulata sa sorbitolom koji ima specifičnu površinu između 0.75–3.5 m2/g da bi se dobila pred-mješavina;
miješanje navedene pred-mješavine sa lubrikantom da bi se dobila konačna mješavina; te
komprimiranje navedene konačne mješavine u tabletu ili sloj tablete.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07104157A EP1970053A1 (en) | 2007-03-14 | 2007-03-14 | Pharmaceutical composition |
| PCT/EP2008/053009 WO2008110599A1 (en) | 2007-03-14 | 2008-03-13 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110012T1 true HRP20110012T1 (hr) | 2011-02-28 |
Family
ID=38179677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110012T HRP20110012T1 (hr) | 2007-03-14 | 2011-01-10 | Farmaceutski pripravak |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US20100143465A1 (hr) |
| EP (2) | EP1970053A1 (hr) |
| JP (1) | JP5742045B2 (hr) |
| KR (1) | KR101503674B1 (hr) |
| CN (1) | CN101641084B (hr) |
| AR (1) | AR065726A1 (hr) |
| AT (1) | ATE493119T1 (hr) |
| AU (1) | AU2008225754B2 (hr) |
| BR (1) | BRPI0808797A2 (hr) |
| CA (1) | CA2680608C (hr) |
| CL (1) | CL2008000733A1 (hr) |
| CO (1) | CO6220927A2 (hr) |
| CY (1) | CY1111350T1 (hr) |
| DE (1) | DE602008004217D1 (hr) |
| DK (1) | DK2120884T3 (hr) |
| EA (1) | EA018574B1 (hr) |
| EC (1) | ECSP099629A (hr) |
| ES (1) | ES2358770T3 (hr) |
| HK (1) | HK1140692A1 (hr) |
| HR (1) | HRP20110012T1 (hr) |
| IL (1) | IL200125A (hr) |
| MA (1) | MA31251B1 (hr) |
| MX (1) | MX2009009201A (hr) |
| MY (1) | MY145089A (hr) |
| NZ (1) | NZ580185A (hr) |
| PE (1) | PE20090165A1 (hr) |
| PL (1) | PL2120884T3 (hr) |
| PT (1) | PT2120884E (hr) |
| RS (1) | RS51584B (hr) |
| SI (1) | SI2120884T1 (hr) |
| TN (1) | TN2009000371A1 (hr) |
| TW (1) | TWI406678B (hr) |
| UA (1) | UA96982C2 (hr) |
| UY (1) | UY30961A1 (hr) |
| WO (1) | WO2008110599A1 (hr) |
| ZA (1) | ZA200905224B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| EP2203158A4 (en) * | 2007-10-30 | 2012-12-26 | Reddys Lab Ltd Dr | PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE |
| WO2009135646A2 (en) | 2008-05-05 | 2009-11-12 | Farmaprojects, Sa | Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale |
| CZ301070B6 (cs) * | 2008-07-31 | 2009-10-29 | Zentiva, A. S. | Telmisartan tablety |
| GB0822171D0 (en) * | 2008-12-04 | 2009-01-14 | Arrow Int Ltd | Temisartan formulations |
| EP2432452B1 (de) | 2009-05-20 | 2016-07-27 | Boehringer Ingelheim Vetmedica GmbH | Pharmazeutische telmisartan-trinklösung |
| WO2013142314A1 (en) * | 2012-03-19 | 2013-09-26 | Althera Life Sciences, Llc | Oral tablet formulation consisting of immediate release rosuv astatin and extended release metformin |
| JP6344678B2 (ja) * | 2013-09-27 | 2018-06-20 | キョーリンリメディオ株式会社 | テルミサルタン含有製剤及びその製造方法 |
| JP6096328B2 (ja) * | 2014-02-10 | 2017-03-15 | 富士フイルム株式会社 | 口腔内崩壊錠 |
| BE1021954B1 (nl) * | 2014-06-05 | 2016-01-28 | Syral Belgium Nv | Samenstelling van sorbitol met lage friabiliteit |
| FR3023128B1 (fr) | 2014-07-01 | 2017-11-10 | Roquette Freres | Nouvelle composition edulcorante |
| JP5871294B1 (ja) * | 2015-02-27 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 即時放出経口錠剤 |
| KR20170001921A (ko) | 2015-06-26 | 2017-01-05 | 대원제약주식회사 | 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법 |
| CN106420739A (zh) * | 2016-10-31 | 2017-02-22 | 扬子江药业集团四川海蓉药业有限公司 | 一种替米沙坦氨氯地平双层片及其制备方法 |
| CN106800537B (zh) | 2017-01-18 | 2019-02-01 | 广东隆赋药业股份有限公司 | 丁苯酞-替米沙坦杂合物及其制备方法和用途 |
| CN109316451B (zh) * | 2017-07-31 | 2022-07-01 | 武汉朗来科技发展有限公司 | 治疗高血压和相关疾病的口服固体制剂 |
| EP3787596A1 (en) | 2018-05-02 | 2021-03-10 | Ferring B.V. | Improved pharmaceutical formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3245170A1 (de) * | 1982-12-07 | 1984-06-07 | Merck Patent Gmbh, 6100 Darmstadt | Verbesserter sorbit, verfahren zur herstellung und verwendung |
| WO2000027397A1 (en) * | 1998-11-06 | 2000-05-18 | Glaxo Group Limited | Antihypertensive medicaments containing lacidipine and telmisartan |
| FR2787110B1 (fr) * | 1998-12-11 | 2001-02-16 | Roquette Freres | Sorbitol pulverulent et son procede de preparation |
| ATE380547T1 (de) * | 2002-01-16 | 2007-12-15 | Boehringer Ingelheim Pharma | Zweischichtige pharmazeutische tablette enthaltend telmisartan und hydrochlorothiazid |
| DE10244681A1 (de) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
| DE102004008804A1 (de) * | 2004-02-20 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mehrschichttablette |
| US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
| EA013053B1 (ru) * | 2004-11-05 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Двуслойная таблетка, содержащая телмисартан и амлодипин |
| US20060159747A1 (en) * | 2004-12-17 | 2006-07-20 | Boehringer Ingelheim International Gmbh | Telmisartan and hydrochlorothiazide combination therapy |
| CN101080225A (zh) * | 2004-12-17 | 2007-11-28 | 贝林格尔·英格海姆国际有限公司 | 包含替米沙坦及氢氯噻嗪的组合治疗 |
-
2007
- 2007-03-14 EP EP07104157A patent/EP1970053A1/en not_active Ceased
-
2008
- 2008-03-12 CL CL200800733A patent/CL2008000733A1/es unknown
- 2008-03-12 PE PE2008000465A patent/PE20090165A1/es not_active Application Discontinuation
- 2008-03-13 TW TW097108903A patent/TWI406678B/zh not_active IP Right Cessation
- 2008-03-13 KR KR1020097021453A patent/KR101503674B1/ko active IP Right Review Request
- 2008-03-13 BR BRPI0808797-0A patent/BRPI0808797A2/pt not_active Application Discontinuation
- 2008-03-13 ES ES08717753T patent/ES2358770T3/es active Active
- 2008-03-13 DE DE602008004217T patent/DE602008004217D1/de active Active
- 2008-03-13 UA UAA200910184A patent/UA96982C2/ru unknown
- 2008-03-13 SI SI200830179T patent/SI2120884T1/sl unknown
- 2008-03-13 NZ NZ580185A patent/NZ580185A/en unknown
- 2008-03-13 WO PCT/EP2008/053009 patent/WO2008110599A1/en active Application Filing
- 2008-03-13 PT PT08717753T patent/PT2120884E/pt unknown
- 2008-03-13 MX MX2009009201A patent/MX2009009201A/es active IP Right Grant
- 2008-03-13 EP EP08717753A patent/EP2120884B1/en not_active Revoked
- 2008-03-13 US US12/530,489 patent/US20100143465A1/en not_active Abandoned
- 2008-03-13 DK DK08717753.1T patent/DK2120884T3/da active
- 2008-03-13 AT AT08717753T patent/ATE493119T1/de active
- 2008-03-13 AU AU2008225754A patent/AU2008225754B2/en active Active
- 2008-03-13 CN CN2008800075975A patent/CN101641084B/zh active Active
- 2008-03-13 MY MYPI20093767A patent/MY145089A/en unknown
- 2008-03-13 RS RS20110032A patent/RS51584B/en unknown
- 2008-03-13 UY UY30961A patent/UY30961A1/es not_active Application Discontinuation
- 2008-03-13 PL PL08717753T patent/PL2120884T3/pl unknown
- 2008-03-13 EA EA200901169A patent/EA018574B1/ru not_active IP Right Cessation
- 2008-03-13 CA CA2680608A patent/CA2680608C/en not_active Expired - Fee Related
- 2008-03-13 JP JP2009553147A patent/JP5742045B2/ja active Active
- 2008-03-13 AR ARP080101038A patent/AR065726A1/es active Pending
-
2009
- 2009-07-27 ZA ZA200905224A patent/ZA200905224B/xx unknown
- 2009-07-28 IL IL200125A patent/IL200125A/en active IP Right Grant
- 2009-09-09 CO CO09096619A patent/CO6220927A2/es not_active Application Discontinuation
- 2009-09-11 EC EC2009009629A patent/ECSP099629A/es unknown
- 2009-09-11 TN TNP2009000371A patent/TN2009000371A1/fr unknown
- 2009-09-11 MA MA32218A patent/MA31251B1/fr unknown
-
2010
- 2010-07-28 HK HK10107229.6A patent/HK1140692A1/xx not_active IP Right Cessation
-
2011
- 2011-01-10 HR HR20110012T patent/HRP20110012T1/hr unknown
- 2011-03-22 CY CY20111100312T patent/CY1111350T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110012T1 (hr) | Farmaceutski pripravak | |
| CA2582049A1 (en) | Bilayer tablet comprising telmisartan and amlodipine | |
| Yoshimura et al. | Impact of the dissolution profile of the cilostazol cocrystal with supersaturation on the oral bioavailability | |
| EP2651398B1 (en) | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| NO20091501L (no) | Farmasoytiske sammensetninger | |
| HRP20150459T1 (hr) | Farmaceutski pripravci na bazi superstruktura antagonista/blokatora angiontenzinskih receptora (arb) i inhibitora neutralne endopeptidaze (nep) | |
| EA200801926A1 (ru) | Таблетки парацетамола с быстрым высвобождением | |
| ES2543427T3 (es) | Forma farmacéutica oral de deferasirox | |
| RU2641198C3 (ru) | Композиции glp-1 пептидов и их получение | |
| US20220016216A1 (en) | Solid glp-1 derivative compositions for oral administration | |
| JP2007527914A5 (hr) | ||
| EA201070160A1 (ru) | Фармацевтическая композиция, содержащая дигидропиридиновый антагонист кальциевого канала, и способ её приготовления | |
| JP2019536761A5 (hr) | ||
| DE602005021475D1 (de) | Magenresistente pharmazeutische dosierform mit n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutaminsäure (lk-423) | |
| WO2016120378A1 (en) | Tablets comprising glp-1 agonist and enteric coating | |
| JP2010540547A5 (hr) | ||
| AR066924A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
| Zhang et al. | Using dissolution and pharmacokinetics studies of crystal form to optimize the original iloperidone | |
| EA201290172A1 (ru) | Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1 | |
| Scalise et al. | Studying interactions of drugs with cell membrane nutrient transporters: new frontiers of proteoliposome nanotechnology | |
| TR201906158T4 (tr) | Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar. | |
| Lu et al. | Identification, Synthesis, and Comprehension of an Imidazole N-3 Regioisomeric Impurity of Olmesartan Medoxomil Key Intermediate | |
| Wang et al. | Collecting the molecular and ionization states of Irbesartan in the solid state | |
| MX2012001393A (es) | Composiciones farmacéuticas de liberación controlada de milnacipran. | |
| WO2006111853A3 (en) | Stable solid dosage forms of acid labile drug |